Taking the fight to their realm: the role of patent oppositions in the struggle for access to medicines.
When it amended its patent laws in 2005, in accordance with the TRIPS (Trade-related Aspects of Intellectual Property Rights) agreement, India was forced to recognize a 20-year period of patent protection for pharmaceuticals, placing the continued ability of Indian generic companies to manufacture affordable antiretroviral drugs (ARVs) in jeopardy. In this article, which is based on a presentation at an abstract-driven session at the conference, Chan Park discusses the successes and challenges experienced by Indian health groups in their novel efforts to oppose the granting of patents for critical drugs.